Pliant Therapeutics, Inc. Common Stock
PLRXPliant Therapeutics, Inc. (PLRX) is a biotechnology company focused on developing therapies for fibrotic diseases. The company aims to create innovative treatments targeting the underlying mechanisms of fibrosis, primarily focusing on conditions such as idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders. Pliant leverages its expertise in fibrosis biology to develop small molecule therapeutics designed to modulate key pathways involved in fibrosis, with the goal of improving patient outcomes.
Company News
Pliant Therapeutics presented updated Phase 1 trial data for PLN-101095, an integrin inhibitor combined with pembrolizumab, showing encouraging results in immune checkpoint inhibitor-refractory patients. The drug demonstrated confirmed responses with 89% average tumor reduction and 19-month median time on treatment. The company has initiated a Ph...
Pliant Therapeutics has voluntarily paused enrollment and dosing in its ongoing BEACON-IPF Phase 2b trial of bexotegrast, leading to a significant drop in its stock price. Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors who suffered significant losses.
Pliant Therapeutics has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis, following a recommendation by the trial's independent Data Safety Monitoring Board. The company will monitor current patients while the data is reviewed.
Pliant Therapeutics presented positive data from the INTEGRIS-PSC trial, showing that their drug bexotegrast improved markers and symptoms of cholestasis and stabilized liver fibrosis in patients with primary sclerosing cholangitis.
Pliant Therapeutics' Chief Business Officer Hans Hull sold 9,900 shares of the company's common stock, valued at over $114,000. The sale was part of a nondiscretionary plan to satisfy withholding tax liabilities related to the vesting of performance-vested stock units.
